Cargando…
Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin
Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss. The retrospective study is to investigate the in vitro susceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of bacterial e...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342408/ https://www.ncbi.nlm.nih.gov/pubmed/34354181 http://dx.doi.org/10.1038/s41598-021-95458-w |
_version_ | 1783734062760853504 |
---|---|
author | Chen, Kuan-Jen Sun, Ming-Hui Hou, Chiun-Ho Chen, Hung-Chi Chen, Yen-Po Wang, Nan-Kai Liu, Laura Wu, Wei-Chi Chou, Hung-Da Kang, Eugene Yu-Chuan Lai, Chi-Chun |
author_facet | Chen, Kuan-Jen Sun, Ming-Hui Hou, Chiun-Ho Chen, Hung-Chi Chen, Yen-Po Wang, Nan-Kai Liu, Laura Wu, Wei-Chi Chou, Hung-Da Kang, Eugene Yu-Chuan Lai, Chi-Chun |
author_sort | Chen, Kuan-Jen |
collection | PubMed |
description | Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss. The retrospective study is to investigate the in vitro susceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of bacterial endophthalmitis isolates in specimens at a tertiary referral center from January 1996 to April 2019 in Taiwan. Overall, 450 (49.9%) isolates were Gram positive, 447 (49.6%) were Gram negative, and 4 (0.4%) were Gram variable. In Gram-positive isolates, coagulase-negative staphylococci were the most commonly cultured bacteria (158, 35.1%), followed by Streptococci (100, 22.2%), Enterococci (75, 16.7%), and Staphylococcus aureus (70, 15.6%). In Gram-negative isolates, they were Klebsiella pneumoniae (166, 37.1%) and Pseudomonas aeruginosa (131, 29.3%). All Gram-positive organisms were susceptible to vancomycin, with the exception of one Enterococcus faecium isolate (1/450, 0.2%). Of the Gram-negative isolates, 96.9% and 93.7% were susceptible to ceftazidime and amikacin, respectively. Nine isolates (9/447, 2.0%) were multidrug-resistant Gram-negative bacteria, comprising K. pneumoniae (4/164, 2.4%), Acinetobacter baumannii (2/3, 67%), and Stenotrophomonas maltophilia (3/18, 17%). In conclusion, in vitro susceptibility testing revealed that vancomycin remains the suitable antibiotic treatment for Gram-positive endophthalmitis. Ceftazidime and amikacin provide approximately the same degree of Gram-negative coverage. Multidrug-resistant bacterial endophthalmitis was uncommon. |
format | Online Article Text |
id | pubmed-8342408 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-83424082021-08-06 Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin Chen, Kuan-Jen Sun, Ming-Hui Hou, Chiun-Ho Chen, Hung-Chi Chen, Yen-Po Wang, Nan-Kai Liu, Laura Wu, Wei-Chi Chou, Hung-Da Kang, Eugene Yu-Chuan Lai, Chi-Chun Sci Rep Article Bacterial endophthalmitis is a rare intraocular infection, and prompt administration of intravitreal antibiotics is crucial for preventing severe vision loss. The retrospective study is to investigate the in vitro susceptibility to the antibiotics vancomycin, amikacin, and ceftazidime of bacterial endophthalmitis isolates in specimens at a tertiary referral center from January 1996 to April 2019 in Taiwan. Overall, 450 (49.9%) isolates were Gram positive, 447 (49.6%) were Gram negative, and 4 (0.4%) were Gram variable. In Gram-positive isolates, coagulase-negative staphylococci were the most commonly cultured bacteria (158, 35.1%), followed by Streptococci (100, 22.2%), Enterococci (75, 16.7%), and Staphylococcus aureus (70, 15.6%). In Gram-negative isolates, they were Klebsiella pneumoniae (166, 37.1%) and Pseudomonas aeruginosa (131, 29.3%). All Gram-positive organisms were susceptible to vancomycin, with the exception of one Enterococcus faecium isolate (1/450, 0.2%). Of the Gram-negative isolates, 96.9% and 93.7% were susceptible to ceftazidime and amikacin, respectively. Nine isolates (9/447, 2.0%) were multidrug-resistant Gram-negative bacteria, comprising K. pneumoniae (4/164, 2.4%), Acinetobacter baumannii (2/3, 67%), and Stenotrophomonas maltophilia (3/18, 17%). In conclusion, in vitro susceptibility testing revealed that vancomycin remains the suitable antibiotic treatment for Gram-positive endophthalmitis. Ceftazidime and amikacin provide approximately the same degree of Gram-negative coverage. Multidrug-resistant bacterial endophthalmitis was uncommon. Nature Publishing Group UK 2021-08-05 /pmc/articles/PMC8342408/ /pubmed/34354181 http://dx.doi.org/10.1038/s41598-021-95458-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Chen, Kuan-Jen Sun, Ming-Hui Hou, Chiun-Ho Chen, Hung-Chi Chen, Yen-Po Wang, Nan-Kai Liu, Laura Wu, Wei-Chi Chou, Hung-Da Kang, Eugene Yu-Chuan Lai, Chi-Chun Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin |
title | Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin |
title_full | Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin |
title_fullStr | Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin |
title_full_unstemmed | Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin |
title_short | Susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin |
title_sort | susceptibility of bacterial endophthalmitis isolates to vancomycin, ceftazidime, and amikacin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342408/ https://www.ncbi.nlm.nih.gov/pubmed/34354181 http://dx.doi.org/10.1038/s41598-021-95458-w |
work_keys_str_mv | AT chenkuanjen susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT sunminghui susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT houchiunho susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT chenhungchi susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT chenyenpo susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT wangnankai susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT liulaura susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT wuweichi susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT chouhungda susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT kangeugeneyuchuan susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin AT laichichun susceptibilityofbacterialendophthalmitisisolatestovancomycinceftazidimeandamikacin |